Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 3Unknown 2Terminated 2Recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Polycystic Ovary Syndrome 2Weight Gain 1Diabetes Mellitus, Type 2 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × empagliflozin × Clear all
NCT06140108 2025-05-14

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

SINA Health Education and Welfare Trust

Phase 2/3 Completed
70 enrolled

Polycystic Ovary Syndrome, Weight Gain

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

Completed
344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

NCT03008551 2019-07-15

Empagliflozin vs Metformin in PCOS

Hull University Teaching Hospitals NHS Trust

Phase 2/3 Completed
40 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡